EUCTR2011-003168-63-DE进行中（未招募）1 期
Phase-II study evaluating midostaurin in induction, consolidation andmaintenance therapy also after allogeneic blood stem cell transplantationin patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication AMLSG 16-10 - AMLSG 16-10
niversity Hospital Ulm0 个研究点目标入组 440 人开始时间: 2012年1月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 440
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with confirmed diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification)
- •Presence of FLT3-ITD assessed in the central AMLSG reference laboratories
- •Patients considered eligible for intensive chemotherapy
- •WHO performance status of = 2
- •Age = 18 years and = 70 years with the capacity to give informed consent
- •No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis (= 7 days)
- •Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration (Women of childbearing potential” is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months)
- •Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for 5 months after the last dose of chemotherapy
- •Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner’s vasectomy). Hormonal contraception is an inadequate method of birth control
- •Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy (while on therapy and for 5 months after the last dose of chemotherapy)
- •Signed written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 378
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 62
排除标准
- •AML with the following recurrent genetic abnormalities (according to WHO 2008):
- •AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
- •AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
- •AML with t(15;17)(q22;q12); PML-RARA (or variant translocations with other RARA gene fusions)
- •Performance status WHO >2
- •Patients with ejection fraction < 50% ECHO scan within 14 days of day 1
- •Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder)
- •Uncontrolled infection
- •Severe neurological or psychiatric disorder interfering with ability of giving an informed consent
- •Patients with a currently active” second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active” malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year
- •Known positive for HIV; active HBV, HCV, or Hepatitis A infection
- •Bleeding disorder independent of leukemia
- •No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation.
- •No consent for biobanking.
研究者
相似试验
进行中（未招募）
1 期
Phase-II study evaluating midostaurin in induction, consolidation andmaintenance therapy also after allogeneic blood stem cell transplantationin patients with newly diagnosed acute myeloid leukemia exhibiting a FLT3 internal tandem duplication AMLSG 16-10EUCTR2011-003168-63-ATniversity Hospital Ulm440
进行中（未招募）
2 期
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLFLT3-mutated Acute Myeloid LeukemiaNCT03591510Novartis Pharmaceuticals22
已完成
2 期
Protocol in Acute Myeloid Leukemia With FLT3-ITDAcute Myeloid LeukemiaNCT01477606University of Ulm451
终止
2 期
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell TransplantationAcute Myeloid Leukemia, AdultNCT03951961University of Jena1
已完成
2 期
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaSystemic Mastocytosis, Aggressive (ASM)Leukemia, Mast CellHematological Non-mast Cell Lineage Disease (AHNMD)NCT00233454Jason Robert Gotlib26